Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
about
AXL kinase as a novel target for cancer therapyTargeting the TAM Receptors in LeukemiaSelective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.GAS6 expression identifies high-risk adult AML patients: potential implications for therapyAxl as a mediator of cellular growth and survivalEfficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.Targeted drug discovery for pediatric leukemia.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.Granulocyte colony-stimulating factor produces long-term changes in gene and microRNA expression profiles in CD34+ cells from healthy donors.Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication.Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study
P2860
Q26863442-6D24B91A-EF6B-42DA-941E-75001DA76ABCQ28078654-F1D639A2-1F1A-4BB9-BDB8-C95F89F0BAD7Q33442949-F9C0AE12-B86C-4F9A-BB33-2F5E836F4AD2Q33717707-757C6F81-4759-4893-BCA3-3051385E3209Q34619118-1C408DD5-6FA7-473A-8F27-01EF63D78F83Q35740058-7DA0D26B-C924-4ABD-926B-EA328E2DA16EQ35750567-F8194390-F323-412E-8A4F-48E724B13700Q36865880-31D6C5B0-F8C7-4DE4-B699-14C4B9FBFC1AQ36989223-F3C6AC20-B91B-4C3A-ADED-532C55094F4BQ37221579-D20D04A9-A82C-43FC-BAF4-7DC26CCEC91FQ37545045-863913E5-83B3-4BEC-B6A7-F0DEB756E562Q37552014-55EAC9D7-0B5C-4C7C-BB1E-2F38EFCA1C53Q38168893-137CDCD2-35B7-4880-9FDA-61B684CD7FF7Q38401664-598EC0A7-D47A-482C-B523-0A597478DD62Q38569175-6B6404D4-5F25-4046-856E-33D0511DEDF2Q38853220-68255AE0-E13C-4366-AA12-1EF983448671Q42363757-0C3AD198-8139-4227-BBFC-271EB0DF5A43Q43070849-F0CFE455-20A8-4569-842B-97B27DF70C15Q43238541-01A54E7B-A341-45F6-B962-9D5A353FCC16Q47142820-371EB07D-735E-439A-9E3B-FA65650A5997Q47965108-78430B73-F272-45C8-B731-5DF466E65B05Q53509565-B4771F4F-B363-4613-A4B9-0B0DFFAD6E50Q54160284-0AD43953-6E22-4C17-9F04-ABF6F189DF8AQ54297620-492615D1-C162-4F6E-958E-91142442B5ADQ58785754-2C448797-4768-4474-B429-CDE35F4C2755
P2860
Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Inhibition of the receptor tyr ...... potential therapeutic target.
@ast
Inhibition of the receptor tyr ...... potential therapeutic target.
@en
type
label
Inhibition of the receptor tyr ...... potential therapeutic target.
@ast
Inhibition of the receptor tyr ...... potential therapeutic target.
@en
prefLabel
Inhibition of the receptor tyr ...... potential therapeutic target.
@ast
Inhibition of the receptor tyr ...... potential therapeutic target.
@en
P2093
P2860
P1433
P1476
Inhibition of the receptor tyr ...... potential therapeutic target.
@en
P2093
Anjali Mishra
Il-Kyoo Park
Jason Chandler
Michael A Caligiuri
Susan P Whitman
P2860
P304
P356
10.1182/BLOOD-2012-07-444018
P407
P577
2013-01-15T00:00:00Z